A Phase 1 Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects

NCT01396135 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: CP-601,927
DRUG: CP-601,927
DRUG: CP-601,927
DRUG: Placebo
DRUG: CP-601,927
DRUG: Placebo

Sponsor

Pfizer